ASPS Addresses Concerns Regarding BOTOX Treatments

ARLINGTON HEIGHTS, Ill. – The American Society of Plastic Surgeons (ASPS) today addressed concerns regarding the use of botulinum toxin products and adverse events following a recent petition from a consumer group.

On January 23, Public Citizen requested the U.S. Food and Drug Administration (FDA) implement labeling changes and a written communication to physicians.

More than one million people have been treated with BOTOX Cosmetic. Complications and adverse events from BOTOX Cosmetic treatments are rare.

“As patient advocates, plastic surgeons are primarily concerned about the safety of our patients,” said Richard A. D’Amico, MD, ASPS president. “We have a keen interest and expertise in informing patients about intended use of the product and risks and benefits.”

ASPS believes that the safety issues identified in the petition are currently addressed in the manufacturer labeling with detailed information and guidance, including approved indications, contraindications, warnings, drug interactions, precautions, and reported adverse event information.

The ASPS works closely with the FDA on a range of issues and strongly supports existing labeling requirements agreed to between the manufacturers and the FDA.

Almost all drugs and devices have adverse events and complications associated with them. It is important for physicians to have a proper medical history of patients prior to them receiving any treatment. Patients should be fully informed and educated about risks and benefits.